Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zoster vaccine recombinant, adjuvanted
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Shingrix is a non-live, recombinant subunit vaccine developed by GSK for the prevention of herpes zoster (shingles) and postherpetic neuralgia. It consists of the varicella-zoster virus (VZV) glycoprotein E (gE), which is the most abundant glycoprotein in VZV-infected cells and a primary target for T-cell responses, produced in Chinese Hamster Ovary (CHO) cells. The vaccine is formulated with the AS01B adjuvant system, a liposome-based formulation containing 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist, and QS-21, a saponin extracted from the Quillaja saponaria tree. This adjuvant system is designed to enhance the magnitude and duration of the cellular and humoral immune response, particularly in older adults and immunocompromised individuals where immune senescence is a factor. It is administered as a two-dose intramuscular series.
- Brand names
- Shingrix
- Other names
- recombinant adjuvanted zoster vaccineRZVrecombinant zoster vaccine
02
Targets
gE (VZV glycoprotein E)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on zoster vaccine recombinant, adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zoster vaccine recombinant, adjuvanted.